Hidehito Horinouchi summarizes some abstracts of WCLC24 part 3
Hidehito Horinouchi shared on X:
Advancing Multimodal Therapies in Stage III NSCLC
Chairs: Feng-Ming Spring Kong, and Erin Gillaspie.
Osimertinib After Definitive CRT in Unresectable Stage III EGFR-mutated NSCLC: Safety Outcomes from the Phase 3 LAURA Study.
Chairs: Caicun Zhou, and Heather Wakelee
Safety and Efficacy of BAY 2927088 In Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study.
Mesothelioma, Thymoma, and Other Thoracic Tumors.
Chairs: Prasad Adusumilli, and Sonja Klebe.
Radiation Approaches in Thymic Malignancies.
Patient Navigation and Social Justice: Case Presentation.
Chairs: Stephanie McDonald.
Increased Access for Clinical Trials for Black Americans and Building Clinical Access Pathways in Historically Marginalized Communities in Boston.
Expanding Eligibility for Lung Cancer Screening.
Authors: Chi-Fu Jeffrey Yang, and Annette Maree McWilliams.
Defining Eligibility for Lung Cancer Screening in Asia
Novel Immunotherapeutics: Raising the Bar.
Chairs: Luis Raez, and Delvys Rodriguez-Abreu.
Cancer Vaccines and Oncolytic Viruses.
Chairs: Chunxue Bai, Karen Kelly, Yi-Long Wu, and Caicun Zhou.
Lung Cancer Prevention and Biomarker- Guided Treatment in China During the Last Half Century.
Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital. He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.